Cationic niosomes have become important non-viral vehicles for transporting a good number of small drug molecules and macromolecules. Growing interest shown by these colloidal nanoparticles in therapy is determined by their structural similarities to liposomes. Cationic niosomes are usually obtained from the self-assembly of non-ionic surfactant molecules. This process can be governed not only by the nature of such surfactants but also by others factors like the presence of additives, formulation preparation and properties of the encapsulated hydrophobic or hydrophilic molecules. This review is aimed at providing recent information for using cationic niosomes for gene delivery purposes with particular emphasis on improving the transportation of antisense oligonucleotides (ASOs), small interference RNAs (siRNAs), aptamers and plasmids (pDNA).
Non-viral vectors have emerged as a promising alternative to viral gene delivery systems due to their safer profile. Among non-viral vectors, recently, niosomes have shown favorable properties for gene delivery, including low toxicity, high stability, and easy production. The three main components of niosome formulations include a cationic lipid that is responsible for the electrostatic interactions with the negatively charged genetic material, a non-ionic surfactant that enhances the long-term stability of the niosome, and a helper component that can be added to improve its physicochemical properties and biological performance. This review is aimed at providing recent information about niosome-based non-viral vectors for gene delivery purposes. Specially, we will discuss the composition, preparation methods, physicochemical properties, and biological evaluation of niosomes and corresponding nioplexes that result from the addition of the genetic material onto their cationic surface. Next, we will focus on the in situ application of such niosomes to deliver the genetic material into immune-privileged tissues such as the brain cortex and the retina. Finally, as future perspectives, non-invasive administration routes and different targeting strategies will be discussed.
Nanodiamonds
(NDs) are promising materials for gene delivery because
of their unique physicochemical and biological features, along with
their possibility of combination with other nonviral systems. Our
aim was to evaluate the biophysical performance of NDs as helper components
of niosomes, named nanodiasomes, to address a potential nonviral gene
delivery nanoplatform for therapeutic applications in central nervous
system (CNS) diseases. Nanodiasomes, niosomes, and their corresponding
complexes, obtained after genetic material addition at different ratios
(w/w), were evaluated in terms of physicochemical properties, cellular
uptake, intracellular disposition, biocompatibility, and transfection
efficiency in HEK-293 cells. Nanodiasomes, niosomes, and complexes
fulfilled the physicochemical features for gene therapy applications.
Biologically, the incorporation of NDs into niosomes enhanced 75%
transfection efficiency (
p
< 0.001) and biocompatibility
(
p
< 0.05) to values over 90%, accompanied by
a higher cellular uptake (
p
< 0.05). Intracellular
trafficking analysis showed higher endocytosis via clathrins (
p
< 0.05) in nanodiaplexes compared with nioplexes, followed
by higher lysosomal colocalization (
p
< 0.05),
that coexisted with endosomal escape properties, whereas endocytosis
mediated by caveolae was the most efficient pathway in the case of
nanodiaplexes. Moreover, studies in CNS primary cells revealed that
nanodiaplexes successfully transfected neuronal and retinal cells.
This proof-of-concept study points out that ND integration into niosomes
represents an encouraging nonviral nanoplatform strategy for the treatment
of CNS diseases by gene therapy.
Lipid nanocarriers, such as niosomes, are considered attractive candidates for non-viral gene delivery due to their suitable biocompatibility and high versatility. In this work, we studied the influence of incorporating chloroquine in niosomes biophysical performance, as well as the effect of non-ionic surfactant composition and protocol of incorporation in their biophysical performance. An exhaustive comparative evaluation of three niosome formulations differing in these parameters was performed, which included the analysis of their thermal stability, rheological behavior, mean particle size, dispersity, zeta potential, morphology, membrane packing capacity, affinity to bind DNA, ability to release and protect the genetic material, buffering capacity and ability to escape from artificially synthesized lysosomes. Finally, in vitro biological studies were, also, performed in order to determine the compatibility of the formulations with biological systems, their transfection efficiency and transgene expression. Results revealed that the incorporation of chloroquine in niosome formulations improved their biophysical properties and the transfection efficiency, while the substitution of one of the non-ionic surfactants and the phase of addition resulted in less biophysical variations. Of note, the present work provides several biophysical parameters and characterization strategies that could be used as gold standard for gene therapy nanosystems evaluation.
Biophysical screening of the nanodiasome formulations composed of niosomes with nanodiamonds as helper component, physicochemical characterization of nanodiasomes at different ND/DOTMA mass ratios (including Figure S1 showing the data), transfection efficiency of nanodiasomes at different ND/DOTMA mass ratios, Figure S2 showing normalized percentages of EGFP positive live cells and cell viability, and description of the videos (PDF)■ AUTHOR INFORMATION
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.